SureAdhere and VDOT Background

Originally developed in a rigorous academic environment at the University of California San Diego (UCSD), the SureAdhere platform has been heavily evaluated through partnerships between academic researchers and public health organizations across a diverse range of resource settings and context globally. To date, there are 28 articles that evaluate SureAdhere’s VOT platform for TB treatment support published in academic journals, 17 of which were either authored by the original UCSD research team prior to SureAdhere’s commercialization, or which utilized SureAdhere to augment VOT for a new environment.

This rich evidence base has been used to inform digital adherence guidance at the CDC and WHO - both of which have approved VOT as an acceptable alternative to in-person DOT where appropriate.

A sample of 5 studies are highlighted below with summarized findings including a recent  study in JAMA Network Open (conducted using SureAdhere’s VOT platform at the NYC Department of Health) demonstrates that electronic DOT is non-inferior to in-person DOT for TB treatment adherence, which will likely strengthen the CDC’s current guidance on eDOT for TB in the US and support further uptake of VOT as a chosen standard of care for TB treatment support globally. 

Evidence

In addition to the 5 studies noted above, an exhaustive list of research on VOT is included below: